Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models
| Autor: | Jing Guo, Guiying Xu, Chuanbin Mao, Rongfei Wei |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Translational Oncology, Vol 13, Iss 9, Pp 100804- (2020) |
| Druh dokumentu: | article |
| ISSN: | 1936-5233 24694487 |
| DOI: | 10.1016/j.tranon.2020.100804 |
| Popis: | Despite the side effects, chemotherapy is one of the most common treatments in colorectal cancer (CRC). An open-ended question about CRC chemotherapy, which has been discussed quite often, is with respect to the validation of prognostic or predictive factors. It is believed that personalized chemotherapy can improve the treatment outcome of patients with colorectal tumors. Though, Smurf1 is highly expressed in multiple tumors and plays a critical role in the occurrence and development of multiple cancers, it’s role in the susceptibility of CRC response to chemotherapy is still unknown, Therefore, the study aimed to understand the role of Smurf1 in the susceptibility of CRC response to chemotherapy. The study showed that the knockdown of Smurf1 increases gemcitabine and cisplatin-induced HCT116 cells apoptosis in vitro. Furthermore, in vivo experiments showed that tumors that had low Smurf1 expression exhibited enhanced gemcitabine, cisplatin, and gemcitabine plus cisplatin anti-tumor effects in HCT116 cell-derived xenograft (CDX) models and patient-derived xenograft (PDX) models. In conclusion, the results indicated that Smurf1 inhibits the chemosensitivity of CRC to gemcitabine, cisplatin, and gemcitabine plus cisplatin. Therefore, downregulati1ng the Smurf1 expression is a potential strategy to increase the efficacy of gemcitabine and cisplatin in CRC patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|